Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUNRAY-02: Olomorasib plus standard immunochemotherapy in KRAS G12C-mutated NSCLC
CTR20250763Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of olomorasib in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Started Apr 2025; status: active.
02
Drugs
olomorasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20250763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250763.